← Back to Patent Explorer
US6120847A Expired / Lapsed US ⏱️ 0.0 years remaining

Surface treatment method for stent coating

Assignee: Boston Scientific Scimed Inc
•
Filing: 1999-01-08
•
Granted: 2000-09-19
•
Expires: 2019-01-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method is provided for eliminating surface imperfections on a medical device having a drug release coating including a therapeutic substance in a polymeric carrier disposed on at least a portion of the medical device. The medical device is preferably a stent including wire-like members interconnected to form struts with open interstices therebetween. A therapeutic substance incorporate into a polymeric carrier is disposed on the surface of the stent through which process imperfections including polymeric fibers, polymeric particles or other polymeric surface aberrations or imperfections are formed. This imperfections are eliminated by contacting the polymeric coating with a vaporized solvent for a specified period of time.

Inventors

  • 👤 Dachuan Yang
  • 👤 Carmen Jacob
  • 👤 Lixiao Wang

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 16:29
CPC Classifications
B; B05; B05D; B05D3/00; B05D3/12; A; A61; A61L; A61L31/00; A61L31/08; A61L31/10

Claims Analysis

Total Claims: 28
Claim 1
Independent Claim 86 words
A method for eliminating polymeric fibers, polymeric particles or other polymeric surface aberrations or imperfections from a polymeric coating on a medical device, the method comprising the steps of: providing a medical device having a surface generally defined by a skeletal frame having spaces therebetween, wherein at least a portion of said surface is coated with a polymeric material, some of said polymeric material extending across said spaces; and, contacting said polymeric coating with a vaporized solvent, thereby eliminating said polymeric material extending across said spaces.
Claim 2
Independent Claim 86 words
A method for eliminating polymeric fibers, polymeric particles or other polymeric surface aberrations or imperfections from a polymeric coating on a medical device, the method comprising the steps of: providing a medical device having a surface generally defined by a skeletal frame having spaces therebetween, wherein at least a portion of said surface is coated with a polymeric material, some of said polymeric material extending across said spaces; and, contacting said polymeric coating with a vaporized solvent, thereby eliminating said polymeric material extending across said spaces.
Claim 3
Dependent Claim 18 words
The method of claim 1, wherein said polymeric material is at least partially soluble in said vaporized solvent.
Claim 4
Dependent Claim 46 words
The method of claim 2, wherein said polymeric material is contacted with said vaporized solvent for between about 0.5 seconds to about 2 hours to thereby eliminate surface fibers, surface particles or other surface aberrations without abrogating the integrity of said polymeric coating over said surface.
Claim 5
Dependent Claim 13 words
The method of claim 2, wherein said vaporized solvent is an organic solvent.
Claim 6
Dependent Claim 33 words
The method of claim 4, wherein said organic solvent is selected from the group consisting of hydrocarbons, polyethers, halocarbons, alkyl amides, cyclic ethers, ethyl acetate, benzene, alkyl-substituted benzene derivatives, alcohols, and combinations thereof.
Claim 7
Dependent Claim 29 words
The method of claim 1, wherein said polymeric coating is selected from the group consisting of polyethylene oxide (PEO), polylactic acid, polyglycolic acid, polycaprolactone, polyurethane, polysiloxane and their copolymers.
Claim 8
Dependent Claim 16 words
The method of claim 1, wherein said polymeric coating includes a therapeutic agent releasably incorporated therein.
Claim 9
Dependent Claim 27 words
The method of claim 7, wherein said therapeutic agent is selected from the group consisting of an anti-thrombogenic agent, an anti-angiogenesis agent, heparin, hirudin, ticlopidine, and Taxol.
Claim 10
Dependent Claim 21 words
The method of claim 1, wherein said contact between said polymeric coating and said vaporized solvent occurs through a dipping process.
Claim 11
Dependent Claim 21 words
The method of claim 1, wherein said contact between said polymeric coating and said vaporized solvent occurs through a spraying process.
Claim 12
Independent Claim 121 words
A method of coating a medical device with a polymeric material wherein said coating is generally free of polymeric strands, polymeric particles or other polymeric surface aberrations, said method comprising the steps of: providing a medical device having a surface generally defined by a plurality of interconnected stunts with open interstitial spaces therebetween, coating at least a portion of said surface with a polymeric material in a solvent carrier; drying said polymeric material by evaporating at least a portion of said solvent carrier to form a dried polymeric coating, wherein some of said dried polymeric material extends across said interstitial spaces; and, contacting said dried polymeric coating with a vaporized solvent, thereby eliminating said polymeric material extending across said interstitial spaces.
Claim 13
Independent Claim 121 words
A method of coating a medical device with a polymeric material wherein said coating is generally free of polymeric strands, polymeric particles or other polymeric surface aberrations, said method comprising the steps of: providing a medical device having a surface generally defined by a plurality of interconnected stunts with open interstitial spaces therebetween, coating at least a portion of said surface with a polymeric material in a solvent carrier; drying said polymeric material by evaporating at least a portion of said solvent carrier to form a dried polymeric coating, wherein some of said dried polymeric material extends across said interstitial spaces; and, contacting said dried polymeric coating with a vaporized solvent, thereby eliminating said polymeric material extending across said interstitial spaces.
Claim 14
Dependent Claim 46 words
The method of claim 11, wherein said polymeric material is contacted with said vaporized solvent for between about 0.5 seconds to about 2 hours to thereby eliminate surface fibers, surface particles or other surface aberrations without abrogating the integrity of said polymeric coating over said surface.
Claim 15
Dependent Claim 13 words
The method of claim 11, wherein said vaporized solvent is an organic solvent.
Claim 16
Dependent Claim 30 words
The method of claim 13, wherein said organic solvent is selected from the group consisting of hydrocarbons, polyethers, cyclic ethers, ethyl acetate, benzene, alkyl-substituted benzene derivatives, alcohols, and combinations thereof.
Claim 17
Dependent Claim 30 words
The method of claim 11, wherein said polymeric coating is selected from the group consisting of polyethylene oxide (PEO), polylactic acid, polyclycolic acid, and polycaprolactone, polyurethane, polysiloxane and their copolymers.
Claim 18
Independent Claim 137 words
A method for coating a stent with a polymeric material having a therapeutic substance dispersed therein for timed release of said therapeutic substance when said stent is implanted wherein said coating is generally free of polymeric strands, polymeric particles or other polymeric surface aberrations, said method comprising the steps of: providing a stent having a surface generally defined by a plurality of interconnected struts with open interstitial spaces therebetween; coating at least a portion of said surface with a polymeric material in a solvent carrier; drying said polymeric material by evaporating at least a portion of said solvent carrier to form a dried polymeric coating, wherein some of said dried polymeric material extends across said interstitial spaces; and, contacting said dried polymeric coating with a vaporized solvent, thereby eliminating said polymeric material extending across said interstitial spaces.
Claim 19
Independent Claim 137 words
A method for coating a stent with a polymeric material having a therapeutic substance dispersed therein for timed release of said therapeutic substance when said stent is implanted wherein said coating is generally free of polymeric strands, polymeric particles or other polymeric surface aberrations, said method comprising the steps of: providing a stent having a surface generally defined by a plurality of interconnected struts with open interstitial spaces therebetween; coating at least a portion of said surface with a polymeric material in a solvent carrier; drying said polymeric material by evaporating at least a portion of said solvent carrier to form a dried polymeric coating, wherein some of said dried polymeric material extends across said interstitial spaces; and, contacting said dried polymeric coating with a vaporized solvent, thereby eliminating said polymeric material extending across said interstitial spaces.
Claim 20
Dependent Claim 18 words
The method of claim 16, wherein said polymeric material is at least partially soluble in said vaporized solvent.
Claim 21
Dependent Claim 46 words
The method of claim 17, wherein said polymeric material is contacted with said vaporized solvent for between about 0.5 seconds to about 2 hours to thereby eliminate surface fibers, surface particles or other surface aberrations without abrogating the integrity of said polymeric coating over said surface.
Claim 22
Dependent Claim 13 words
The method of claim 17, wherein said vaporized solvent is an organic solvent.
Claim 23
Dependent Claim 33 words
The method of claim 19, wherein said organic solvent is selected from the group consisting of hydrocarbons, polyethers, halocarbons, alkyl amides, cyclic ethers, ethyl acetate, benzene, alkyl-substituted benzene derivatives, alcohols, and combinations thereof.
Claim 24
Dependent Claim 29 words
The method of claim 16, wherein said polymeric coating is selected from the group consisting of polyethylene oxide (PEO), polylactic acid, polyglycolic acid, polycaprolactone, polyurethane, polysiloxane, and their copolymers.
Claim 25
Dependent Claim 21 words
The method of claim 16, wherein said contact between said polymeric coating and said vaporized solvent occurs through a dipping process.
Claim 26
Dependent Claim 21 words
The method of claim 16, wherein said contact between said polymeric coating and said vaporized solvent occurs through a spraying process.
Claim 27
Dependent Claim 18 words
The method of claim 16, wherein said therapeutic substances include anti-proliferative agents, anti-thrombogenic agents, or a combination thereof.
Claim 28
Dependent Claim 19 words
The method of claim 16, wherein said therapeutic substance in said polymeric material is contacted with said vaporized solvent.

References Cited (Backward Citations)

US2282274A Cited
US3525634A Cited
US3527650A Cited
US3676171A Cited
US3684553A Cited
US3737499A Cited
US4027676A Cited
US4391797A Cited
US4302418A Cited
US4459317A Cited
US4487808A Cited
US4525409A Cited
US4770664A Cited
US5569469A Cited
US4923464A Cited
US5102417A Cited
US4768507A Cited
EP0274846B1 Cited
US5092885A Cited
EP0294905A1 Cited
US5527337A Cited
US4969890A Cited
US5019096A Cited
WO1990001969A1 Cited
WO1990013332A1 Cited
US4994071A Cited
WO1991007154A1 Cited
WO1991010424A1 Cited
WO1991011193A1 Cited
WO1991012779A1 Cited
US5545208A Cited
EP0470246B1 Cited
US5569463A Cited
US5447724A Cited
WO1992000747A1 Cited
EP0470569A1 Cited
US5222971A Cited
US5449372A Cited
US5304121A Cited
WO1992012717A2 Cited
WO1992015286A1 Cited
US5512055A Cited
WO1993006792A1 Cited
US5514154A Cited
EP0543653A1 Cited
WO1993011120A1 Cited
EP0551182A1 Cited
US5423885A Cited
US5755769A Cited
US5591227A Cited
US5443496A Cited
US5282823A Cited
US5697967A Cited
EP0568310A1 Cited
EP0567816A1 Cited
US5383928A Cited
US5578075A Cited
US5449382A Cited
US5578075B1 Cited
EP0604022A1 Cited
US5443458A Cited
US5419760A Cited
US5733925A Cited
WO1994021308A1 Cited
US5562922A Cited
US5464650A Cited
US5837008A Cited
EP0623354A1 Cited
US5776184A Cited
US5624411A Cited
US5679400A Cited
EP0706376B1 Cited
US5716981A Cited
US5616608A Cited
US5380299A Cited
WO1996003092A1 Cited
WO1996003984A1 Cited
US5626862A Cited
US5651986A Cited
US5660873A Cited
US5700286A Cited
US5637113A Cited
WO1996025176A1 Cited
US5674241A Cited
WO1996026689A1 Cited
US5605696A Cited
US5674242A Cited
US5609629A Cited
WO1998036784A1 Cited
US5779732A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2003-09-19 2004-03-20 2004-09-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2007-09-19 2008-03-20 2008-09-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2011-09-19 2012-03-20 2012-09-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag